TY - JOUR
T1 - Integrated cascade antioxidant nanozymes-Cu5.4O@ CNDs combat acute liver injury by regulating retinol metabolism
AU - Chen, Jiayu
AU - Zhang, Yujie
AU - Deng, Zhichao
AU - Zhu, Yuanyuan
AU - Xu, Chenxi
AU - Gao, Bowen
AU - Wang, Wenlong
AU - Xiao, Jie
AU - Xiao, Zhengtao
AU - Zhang, Mingzhen
AU - Tu, Kangsheng
N1 - Publisher Copyright:
© The author(s).
PY - 2025
Y1 - 2025
N2 - Background: Acute liver failure (ALF) represents a critical medical condition marked by the abrupt onset of hepatocyte damage, commonly induced by etiological factors such as hepatic ischemia/reperfusion injury (HIRI) and drug-induced hepatotoxicity. Across various types of liver injury, oxidative stress, heightened inflammatory responses, and dysregulated hepatic retinol metabolism are pivotal contributors, particularly in the context of excessive reactive oxygen species (ROS). Methods: C-dots were combined with Cu5.4O USNPs to synthesize a cost-effective nanozyme, Cu5.4O@CNDs, which mimics the activity of cascade enzymes. The in vitro evaluation demonstrated the ROS scavenging and anti-inflammatory capacity of Cu5.4O@CNDs. The therapeutic potential of Cu5.4O@CNDs was evaluated in vivo using mouse models of hepatic ischemia/reperfusion injury and LPS/D-GalN induced hepatitis, with transcriptome analysis conducted to clarify the mechanism underlying hepatoprotection. Results: The Cu5.4O@CNDs demonstrated superoxide dismutase (SOD) and catalase (CAT) enzyme activities, as well as hydroxyl radical (·OH) scavenging capabilities, effectively mitigating ROS in vitro. Furthermore, the Cu5.4O@CNDs exhibited remarkable targeting efficacy towards inflammation cells induced by H2O2 and hepatic tissues in murine models of hepatitis, alongside exhibiting favorable biocompatibility in both in vitro and in vivo settings. Moreover, it has been demonstrated that Cu5.4O@CNDs effectively scavenged ROS, thereby enhancing cell survival in vitro. Additionally, Cu5.4O@CNDs exhibited significant therapeutic efficacy in mice models of HIRI and lipopolysaccharide-induced acute lung injury (LPS-ALI). This efficacy was achieved through the modulation of the ROS response and hepatic inflammatory network, as well as the amelioration of disruptions in hepatic retinol metabolism. Conclusions: In summary, this study demonstrates that Cu5.4O@CNDs exhibit significant potential for the treatment of various acute liver injury conditions, suggesting their promise as an intervention strategy for clinical application.
AB - Background: Acute liver failure (ALF) represents a critical medical condition marked by the abrupt onset of hepatocyte damage, commonly induced by etiological factors such as hepatic ischemia/reperfusion injury (HIRI) and drug-induced hepatotoxicity. Across various types of liver injury, oxidative stress, heightened inflammatory responses, and dysregulated hepatic retinol metabolism are pivotal contributors, particularly in the context of excessive reactive oxygen species (ROS). Methods: C-dots were combined with Cu5.4O USNPs to synthesize a cost-effective nanozyme, Cu5.4O@CNDs, which mimics the activity of cascade enzymes. The in vitro evaluation demonstrated the ROS scavenging and anti-inflammatory capacity of Cu5.4O@CNDs. The therapeutic potential of Cu5.4O@CNDs was evaluated in vivo using mouse models of hepatic ischemia/reperfusion injury and LPS/D-GalN induced hepatitis, with transcriptome analysis conducted to clarify the mechanism underlying hepatoprotection. Results: The Cu5.4O@CNDs demonstrated superoxide dismutase (SOD) and catalase (CAT) enzyme activities, as well as hydroxyl radical (·OH) scavenging capabilities, effectively mitigating ROS in vitro. Furthermore, the Cu5.4O@CNDs exhibited remarkable targeting efficacy towards inflammation cells induced by H2O2 and hepatic tissues in murine models of hepatitis, alongside exhibiting favorable biocompatibility in both in vitro and in vivo settings. Moreover, it has been demonstrated that Cu5.4O@CNDs effectively scavenged ROS, thereby enhancing cell survival in vitro. Additionally, Cu5.4O@CNDs exhibited significant therapeutic efficacy in mice models of HIRI and lipopolysaccharide-induced acute lung injury (LPS-ALI). This efficacy was achieved through the modulation of the ROS response and hepatic inflammatory network, as well as the amelioration of disruptions in hepatic retinol metabolism. Conclusions: In summary, this study demonstrates that Cu5.4O@CNDs exhibit significant potential for the treatment of various acute liver injury conditions, suggesting their promise as an intervention strategy for clinical application.
KW - Acute liver injury
KW - C-dots nanozymes
KW - Cu5.4O nanoparticles
KW - Hepatic ischemia-reperfusion injury
KW - Reactive oxygen species
UR - https://www.scopus.com/pages/publications/105004175908
U2 - 10.7150/thno.106811
DO - 10.7150/thno.106811
M3 - 文章
C2 - 40365282
AN - SCOPUS:105004175908
SN - 1838-7640
VL - 15
SP - 5592
EP - 5615
JO - Theranostics
JF - Theranostics
IS - 12
ER -